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Background: Lipoprotein lipase regulates fat uptake into adipose tissue.
Results: A mouse model with increased adipose tissue lipoprotein lipase has improved glucose metabolism when challenged
with a high fat diet.
Conclusion: Increasing adipose tissue lipoprotein lipase improves adipose tissue function.
Significance: Adipose tissue lipoprotein lipase protects against obesity-induced glucose and insulin intolerance.
Lipid accumulation in liver and skeletal muscle contributes to
co-morbidities associated with diabetes and obesity. We made a
transgenic mouse in which the adiponectin (Adipoq) promoter
drives expression of lipoprotein lipase (LPL) in adipocytes to
potentially increase adipose tissue lipid storage. These mice
(Adipoq-LPL) have improved glucose and insulin tolerance as
well as increased energy expenditure when challenged with a
high fat diet (HFD). To identify the mechanism(s) involved, we
determined whether the Adipoq-LPL mice diverted dietary lipid
to adipose tissue to reduce peripheral lipotoxicity, but we found
no evidence for this. Instead, characterization of the adipose
tissue of the male mice after HFD challenge revealed that the
mRNA levels of peroxisome proliferator-activated receptor-␥
(PPAR␥) and a number of PPAR␥-regulated genes were higher
in the epididymal fat pads of Adipoq-LPL mice than control
mice. This included adiponectin, whose mRNA levels were
increased, leading to increased adiponectin serum levels in the
Adipoq-LPL mice. In many respects, the adipose phenotype of
these animals resembles thiazolidinedione treatment except
for one important difference, the Adipoq-LPL mice did not
gain more fat mass on HFD than control mice and did not
have increased expression of genes in adipose such as glycerol
kinase, which are induced by high affinity PPAR agonists.
Rather, there was selective induction of PPAR␥-regulated
genes such as adiponectin in the adipose of the Adipoq-LPL
mice, suggesting that increasing adipose tissue LPL improves
glucose metabolism in diet-induced obesity by improving the
adipose tissue phenotype. Adipoq-LPL mice also have increased energy expenditure.

Lipoprotein lipase (LPL)2 is a central enzyme in lipid metabolism and adipose biology. LPL is synthesized and secreted by
adipocytes and muscle and is transported to the capillary endothelium where it hydrolyzes the triglyceride (TG) core of circulating very low density lipoprotein (VLDL) and chylomicrons.
The hydrolysis products are fatty acids and monoacylglycerol,
which are taken up by the tissue. Depending upon the circumstance, such as the fed or fasting state, LPL delivers fatty acids to
adipose tissue for storage or to heart and skeletal muscle as a
fuel source. Therefore, LPL activity is highly regulated in these
tissues, acting as a “metabolic gatekeeper” (1) to ensure that
fatty acids are delivered to the correct tissue depending upon
the physiological state (2).
In obesity, adipose tissue lipid accumulates up to a point, and
then lipid is stored in ectopic sites such as liver and muscle. This
increases diacylglycerides (DAGs) and ceramides, which inhibit
insulin receptor signaling in these tissues (3). The accumulation
of these ectopic lipids is thus postulated to cause insulin resistance along with inflammation and endoplasmic reticulum
stress (3–5). Consistent with its ability to promote ectopic lipid
accumulation, tissue-specific transgenic expression of LPL in
skeletal muscle and liver induces insulin resistance (6), and LPL
deficiency in muscle protects against insulin resistance in that
tissue (7). Adipose tissue protects against the accumulation of
ectopic lipids in these peripheral tissues by storing fat as neutral
lipid (triglyceride). Lipid diversion into adipose tissue is one of
the mechanisms of insulin sensitization by thiazolidinediones
(TZDs) (8, 9), and LPL is an important gene target of TZDs (10).
As expected, when there is insufficient adipose to store lipid,
such as in adipose-deficient mice and humans, insulin resistance develops (11–13). Together, these observations suggest
that diversion of lipid from muscle and liver into adipose tissue
is generally beneficial.
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In addition to lipid diversion, another predicted effect of
increased adipose LPL is stimulation of PPAR transcription factors by the free fatty acids generated by lipoprotein hydrolysis.
Depending upon the cell type and PPAR transcription factor
expressed, activation of PPAR can have important physiological
consequences. For instance, in macrophages or endothelial
cells, LPL hydrolysis of VLDL activates PPAR transcription factors and has anti-inflammatory effects (14, 15). In muscle, LPL
stimulates PPAR␦, regulating mitochondrial biogenesis (16). In
adipose tissue, LPL is in a positive feedback loop in which LPL
stimulates PPAR␥, and the LPL gene is induced by PPAR␥ (10).
Activation of PPAR␥ in adipose tissue could result in numerous
physiological outcomes, including insulin sensitization.
We have made a transgenic mouse in which the adiponectin
promoter drives the expression of LPL in adipocytes, and these
mice (Adipoq-LPL) have improved glucose tolerance and insulin tolerance when challenged with a high fat diet. We evaluated
whether this was due to reduction of ectopic lipids in skeletal
muscle and liver and/or activation of PPAR␥ in adipose tissue.
We found that the adiponectin promoter used only modestly
increased adipose tissue Lpl over endogenous levels, which was
insufficient to cause a redistribution of lipid. However, there
was sufficient expression of the transgene to improve the white
adipose phenotype by increasing PPAR␥ and PPAR␥-regulated
genes such as adiponectin, resulting in an improved phenotype
after HFD challenge.

EXPERIMENTAL PROCEDURES
Animal Studies—All of the studies involving mice were
approved by the University of Kentucky Institutional Animal
Care and Use Committee. The mice were housed in standard
conditions at 22 °C, with a 14-h light and a 10-h dark cycle, and
ad libitum access to standard rodent diet (Teklad Global 18%
protein rodent diet; 2018; Teklad, Madison, WI) and water.
Mice were given high fat diet (60% kcal from fat; D12492;
Research Diets, New Brunswick, NJ) at the indicated age. Body
composition was determined with an EchoMRI system (Echo
Medical Systems, Houston, TX). Mice were evaluated by indirect calorimetry (TSE Systems, Chesterfield, MO). Wild-type
female C57B6/J mice (The Jackson Laboratory, Bar Harbor,
ME) were used for backcrossing.
Adipoq-LPL Transgenic Mouse—Human LPL was amplified
by PCR using primers that added a 5⬘ HindIII site and a BamHI
site in front of the stop codon using the LPL 3.6 plasmid (17) as
a template. The PCR product was then subcloned into the HindIII and BamHI sites of pCMV-14 to add a C-terminal
3⫻FLAG epitope. Human LPL-3⫻FLAG was then amplified
using a primer that added a ClaI site and 10 bases of its 5⬘-untranslated region, which corresponds to a strong Kozak
sequence, and a 3⬘ primer that added an EcoRV site after the
FLAG epitope stop codon. This PCR product was subcloned
into the ClaI-EcoRV site of adiponectin 5.4, which is a construct
that allows for very specific transgene expression in adipocytes
using a modified adiponectin promoter, from Dr. Philip
Scherer (18). The resultant plasmid was then digested with
XhoI and KpnI to release the adiponectin 5.4 promoter-hLPL3⫻FLAG construct. This was used by the transgenic mouse
facility at the University of Kentucky to make Adipoq-LPL mice;
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there were several founder mice, but only one made detectable
transgene protein. Studies in this work were from mice backcrossed 5– 8 times into C57BL6 mice. Control mice were always
littermate controls.
Glucose and Insulin Tolerance Tests—Blood glucose was
measured using an AlphaTRAK glucometer (32004-02;
Abbott). For glucose tolerance tests, mice were moved to the
procedure room at least 4 h prior to the start of the procedure
and fasted with free access to water. The animals were then
weighed and intraperitoneally injected with D-(⫹)-glucose, 1
mg/kg body weight. Blood glucose levels were measured at
baseline (immediately prior to injection), and at 30, 60, 90, and
180 min. For insulin tolerance tests, the mice were weighed, and
1.0 –1.5 units Regular Human Insulin (Lilly) per kg of body
weight was injected into the intraperitoneal cavity; blood glucose levels were determined at 0, 30, 60, 90, and 180 min.
Analysis of Serum—Adiponectin was quantified with an
ELISA from Alpco (Salem, NH). Insulin and leptin were quantified using Milliplex Multiplex assays (Merck) and imaged on a
Magpix system. Cholesterol was measured with a kit from
Pointe Scientific (Brussels, Belgium); NEFA and triglycerides
were determined with kits from Wako (Osaka, Japan). Serum
was also fractionated on a fast protein liquid chromatography
system to resolve lipoproteins as described (19). We then determined the area under the curve for the VLDL, LDL, and HDL
peaks.
Histochemistry—Slides were deparaffinized and then incubated in Oil Red O (Sigma O0652; 0.3 g/ml in 60% isopropyl
alcohol) for 30 min at room temperature. Slides were dipped in
H2O and coverslipped using a generous amount of aqueous
mounting media.
Gene Expression—Gene expression was determined by real
time reverse transcriptase polymerase chain reaction, as
described previously (20), except that a Qiagen lipid kit (74804)
was used. Standard curves were made from a pool of the cDNA,
and gene expression was normalized to 18 S. This allows for the
measurement of relative changes in gene expression within the
indicated experiment. The primer sequences are in Table 1.
LPL FLAG Expression and Activity—Protein extracts were
made in 50 mM Tris, pH 7.4, 500 mM NaCl, 1% Nonidet P-40,
20% glycerol, 1 mM DTT, 10 mM sodium pyrophosphate, 100
mM potassium fluoride, 1 mM EDTA, 1⫻ Calbiochem protease
inhibitors. The protein concentration was determined with a
Bradford assay using BSA as a standard, and 30 g was run on a
10% SDS-polyacrylamide gel. The proteins were then transferred to nitrocellulose, immunoblotted with the indicated
antibody, and quantified with an Odyssey imaging system (LICOR Biosciences, Lincoln, NE) as described (21). The antibody
against FLAG (2368) was from Cell Signaling (Danvers MA),
and the antibody against actin (A1978) was from Sigma. Heparin release from minced adipose tissue and measurement of
LPL activity were done as described (22).
Energy Metabolism Studies—Mice were placed on a high fat
diet for 12 weeks. The mice were then placed in acclimation
chambers for 1 week and recorded in a TSE indirect calorimetry
system for 1 week. Resting energy expenditure and net food
intake were determined for the mice during the middle 3 days
and analyzed by an ANCOVA-like model in which energy
VOLUME 290 • NUMBER 18 • MAY 1, 2015
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TABLE 1
Primer sequences
Gene
PPAR␣
PPAR␦
PPAR␥1/2
PPAR␥2
Aco
Cpt-1
Total Lpl
Mouse Lpl
CD36
Fabp4
Atgl
Adiponectin
Ucp3
Scd-1
Pepck
Angplt4
Sirt1
Ucp1
Pgc1␣
Glycerol kinase
Oxidized LDL receptor
F4/80
IL-1␤
Mcp-1
LPL transgene
Atp5a1
Cyto c
Sdha
Vdac

Forward primer
ACA
GGC
AGA
TTC
TCG
TCC
TTG
ACT
GGC
ATG
GGT
CAG
CCG
TTC
AGG
CAT
TGA
CAA
TAT
TGA
CCA
TGA
GCA
TTA
AAC
TCT
CCA
GGA
CCC

GGA
AGC
CAG
GCT
AAG
AGT
TGG
CGC
GTG
TGT
TAG
TGG
ATT
TTG
AGG
CCT
TTG
AAA
GGA
ACC
CAG
CTC
ACT
AAA
TCG
CCA
AAT
ACA
ACA

GAG
CTC
ACA
GAT
CCA
TGG
CCG
TCT
GGT
GAT
AGT
ATC
TCA
CGA
GTG
GGG
GCA
CAG
GTG
TGA
CAT
ACC
GTT
ACC
ACG
TGC
CTC
CTC
TAC

CAG
AAC
TGA
GCA
GCG
CTT
CCC
CAG
CTG
GCC
TGC
TGA
AGC
TAC
TCA
ACG
CCG
AAG
ACA
GGA
GGA
TTG
CCT
TGG
GTA
CTC
CAC
CAA
GCC

GGA
ATG
GCC
CTG
TTA
ATC
TGT
ATG
AAG
TTT
TCA
CGA
CAT
ACT
TCC
AGA
ATC
GAT
TAG
TTT
CGA
TGG
GAA
ATC
TCG
TAA
GGT
AAA
GAT

Reverse primer

TTT
GAA
TTC
CCT
CGA
GTG

GC
TG
ACC
AT
G
GTG

CCC
GAC
GTG
GCC
CAC
GAT
CTG
GCA
TGA
CTC
TGC
AGT
GTC
ATT
TCC
CTC
GGA
ATA
CAC
CTG
CAG
CTT

TA
TGG
GGA
GT
CAA
ACG
GTG
AG
ACT
G
CGA
GTG
AGC
CA
TAA
AAC
ACC
GC
TCG
TTC
ACC
GG

AA
A
C
C

AA
CT

T
AA

T

TAC
TCG
GGG
GGA
GGT
TCC
TCC
TTG
GGA
CTG
ACA
ACG
CCT
CGG
TGC
TGA
CCA
TCT
CCA
CCA
AGC
CTT
ATC
GCA
CTC
CCA
ATC
CCA
GTG

CTA
AGC
TGG
ATG
CTG
AGA
TCC
TGT
GGC
CCA
TGA
TCA
GGC
GAT
TTT
CAA
CAG
TGG
CTT
TGT
TTG
CCC
TTT
TTA
CTC
GGT
AGG
CCA
GTT

CGC
TTC
GAC
CGA
CGA
GTC
TCC
TGC
ACG
CTT
GGA
TCT
GAT
TGA
CGA
GCG
CGT
ACT
CAA
GGA
CTT
AGA
TGG
GCT
CAT
CAA
GTA
CTG
TCC

TCA
ATG
TTT
GTG
TGC
CGA
ATC
TTG
GGG
TCC
GCG
TCG
GGT
ATG
TCC
TTA
CAT
GAG
TCC
GTA
TGT
ATC
GGT
TCA
CCA
CAG
TCC
GGT
GTG

GCC
CGG
CCT
GTC
CAA
TTG
CAG
CCA
TCT
TTG
GAT
GCA
TCT
TTC
TGG
CCA
ATC
TCG
ACC
ACG
GGC
CAG
CCG
GAT
GTT
ACG
TCT
ATT
TTG

CTC
ATT
GCT
TTC
ATT
ATT
TTG
TCC
CAA
TGG
GTG
TGA
GTA
TTG
CCA
CAG
ATC
TAG
CAG
GAT
CTT
TCT
TCA
TTA
GAT
TGT
CCC
GAG
GCA

TT
GT
AAT
CA
CC
TTT GC
T
CCA
CAA
TG
CTG
GG
TCG T
CA
GC
CAG
AGG
AAAG
TTC G
CA
TTC C
ACT
CGG GT
AA
CAG
CAG
TAG AA
GA

expenditure was regressed against the final lean mass of the
mice and the genotype.
Mass Spectroscopy—Skeletal muscle (gastrocnemius) and
liver lipids were extracted with acidified organic solvents and
analyzed by HPLC/ESI tandem mass spectroscopy as described
(23–25). There were only five control mice in this experiment
because one mouse was an outlier.
Statistics—Except where otherwise indicated, data for the
two groups of mice were analyzed by an unpaired, two-tailed
Student’s t test. The weight gains on HFD and glucose and
insulin tolerance tests were analyzed by repeated measures
ANOVA. The resting energy expenditure and net food intake
data were analyzed by an ANCOVA-like model with data
related to genotype and lean mass, augmented by random
effects to capture correlations among the repeated measurements on any particular animal. Resting respiratory exchange
ratio data were analyzed by ANCOVA. Statistical significance
was defined by a p value less than 0.05. Data analyses were
carried out using Version 9.3 of SAS software, Graph Pad Prism
5, and JMP Version 10 SAS Institute.

RESULTS
Generation of Adipocyte-specific LPL-expressing Transgenic
Mice—We made a transgenic mouse that expresses human LPL
under the regulation of the adiponectin 5.4-kb promoter (Fig.
1A), which was previously shown to drive gene expression in
adipocytes in a highly specific manner (18). There were several
founder mice that expressed the transgene mRNA, but only one
expressed detectable protein and was phenotyped. The transgene mRNA is expressed specifically in white adipose tissue
(WAT) depots, but not other tissues (Fig. 1B), and the FLAGtagged LPL transgene protein is detected at 56 kilodaltons in
gonadal fat (Fig. 1C). We expected some transgene expression
in brown adipose tissue (BAT) (18), but there was a very low
MAY 1, 2015 • VOLUME 290 • NUMBER 18

FIGURE 1. Transgene design and expression in adipose tissue. A, human
LPL with a C-terminal 3⫻FLAG epitope tag was cloned into a vector containing the adiponectin 5.4-kb promoter. B, mRNA expression of the transgene in
gonadal (GO), inguinal (SQ), retroperitoneal (RP), brown (BAT) adipose tissues;
skeletal muscle (SKM); and the indicated tissues. C, protein expression of the
transgene in gonadal fat of control and Adipoq-LPL male mice after high fat
diet; the mass of the transgene was estimated using the Bio-Rad Precision
Plus Protein Dual Color standard, which is not shown on the cropped image.
D, protein expression of the transgene in BAT of control and Adipoq-LPL male
mice after high fat diet; the positive control (⫹) is gonadal fat from an AdipoqLPL mouse.

expression of the transgene in BAT at both the mRNA (Fig. 1B)
and protein level (Fig. 1D; no expression detected above background). This low expression in BAT was not due to an unexJOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 2. Weight gain of control and Adipoq-LPL mice on HFD. Mice were
fed a HFD as described under “Experimental Procedures” and weighed
weekly. The data are presented as means ⫾ S.E., and the results of a repeated
measures ANOVA are indicated.

TABLE 2
Serum and mouse characterization of male mice
Significant p values are in boldface type.
Parametera

Control

Adipoq-LPL

p

Serum
Fasting glucose (mg/dl)
NEFA (mmol/liter)
Total triglycerides (mg/dl)
Total cholesterol (mg/dl)
Insulin (ng/ml)
Leptin (ng/ml)
Adiponectin (g/ml)b

203.4 ⫾ 3.5
0.695 ⫾ 0.011
59.42 ⫾ 2.98
166.3 ⫾ 7.2
2.5 ⫾ 0.6
6.9 ⫾ 2.9
17.0 ⫾ 1.1

183.1 ⫾ 5.1
0.670 ⫾ 0.081
50.58 ⫾ 4.84
129.5 ⫾ 4.8
2.8 ⫾ 0.8
7.5 ⫾ 1.4
20.9 ⫾ 0.7

0.01
0.77
0.15
0.01
0.76
0.85
0.03

Mouse characterization
Weight at end of study
Gonadal fat pad mass
Fat mass (ECHO MRI)
Lean mass (ECHO MRI)
% fat (mean)

35.2 ⫾ 1.0
1.04 ⫾ 0.04
13.2 ⫾ 0.9
18.9 ⫾ 0.8
41 ⫾ 2

33.1 ⫾ 2.0
1.01 ⫾ 0.04
11.5 ⫾ 1.2
18.8 ⫾ 0.7
37 ⫾ 2

0.36
0.87
0.29
0.92
0.23

a

Adipoq-LPL transgenic male mice and their littermate controls were characterized in a 19-week high fat (60% cal fat) feeding study (n ⫽ 6 control and n ⫽ 6
Adipoq-LPL per group). Data are represented as means ⫾ S.E.
b
n ⫽ 4 per group because serum was depleted for two mice in each group.

pected repression of the adiponectin promoter, which drives
the transgene in the Adipoq-LPL mice, because adiponectin
mRNA expression was similar in control and Adipoq-LPL BAT
(see BAT gene expression below). Thus, the AdipoQ-LPL
transgene is expressed in predominantly WAT depots.
Glucose and Insulin Tolerance—We hypothesized that the
Adipoq-LPL mice would have an improved metabolic phenotype when challenged with a HFD. When challenged with a
HFD (60% kcal fat), male Adipoq-LPL transgenic mice gained
slightly less weight than their littermate controls (Fig. 2), but
there was no statistically significant difference in weight gain
when analyzed by repeated measures ANOVA (Fig. 2, p ⫽ 0.21)
or in weight at the end of the study (Table 2; p ⫽ 0.36). The male
Adipoq-LPL transgenic mice had improved glucose (Fig. 3A,
p ⫽ 0.0028) and insulin (Fig. 3B, p ⫽ 0.028) tolerance. Female
Adipoq-LPL mice had a trend for improved glucose tolerance
(Fig. 3C, p ⫽ 0.06) but not improved insulin tolerance (Fig. 3D,
p ⫽ 0.52). There was no statistically significant difference in
glucose (p ⫽ 0.99) or insulin (p ⫽ 0.28) tolerance in male mice
on a chow diet (Fig. 3, E and F).
Ectopic Lipid Distribution and Serum Lipids—One mechanism for the improved glucose tolerance could be that
increased adipocyte LPL reduces ectopic lipid accumulation in
liver and muscle by diverting it to fat. We stained liver and
muscle from the HFD-fed male mice with Oil Red O and used
mass spectroscopy to measure DAGs, TGs, and ceramides. As
shown in Fig. 4, there was no qualitative difference in Oil Red O
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staining between the control and Adipoq-LPL mice in skeletal
muscle (Fig. 4A) or in liver (Fig. 4B). Consistent with this, there
was also no reduction in triglycerides, DAGs, or ceramides in
these tissues in the Adipoq-LPL mice as measured by mass
spectroscopy (Table 3), and the Adipoq-LPL mice in fact had an
increase in liver TGs. There was also no evidence of increased
fat mass or gonadal fat pad weights in the Adipoq-LPL mice
after challenge with HFD (Table 2). Furthermore, serum NEFA
and triglyceride levels were not significantly reduced in the Adipoq-LPL mice. Together, these results suggest that peripheral
tissues are not protected from lipid accumulation in the Adipoq-LPL mice. Interestingly, the Adipoq-LPL mice had lower
serum cholesterol levels (Table 2) and lower HDL (p ⬍ 0.05)
and LDL (p ⬍ 0.05) when the sera were resolved by size exclusion chromatography (Fig. 5A). We also observed that triglycerides were reduced in the VLDL fraction (Fig. 5B, p ⬍ 0.05).
Together, these data suggest that the Adipoq-LPL male mice
have reduced lipoprotein levels, but this was not sufficient to
protect peripheral tissues from lipid accumulation.
Improved Adipose Tissue Phenotype—An alternative mechanism of improved insulin sensitivity would be that increased
adipocyte LPL stimulates PPAR transcription factors to
improve adipose tissue function. Therefore, we measured the
expression of PPAR transcription factors and well characterized genes that are PPAR-regulated in epididymal adipose tissue. We found that PPAR␥1/2, PPAR␥2, and several known
genes regulated by PPAR␥ (CD36, Adipoq, and Fabp4) were all
higher in the epididymal fat of the Adipoq-LPL mice than control mice after a high fat diet (p ⬍ 0.05; Table 4). Endogenous
Lpl, which is also PPAR␥-regulated, was induced 1.3-fold, and
when we measured total Lpl by using primers that reacted with
both human and mouse Lpl, there was only a 1.6-fold induction;
thus, the adiponectin promoter only modestly increased total
Lpl mRNA, which could explain why the peripheral tissues
were not protected from ectopic lipid accumulation (see
above). We measured heparin releasable LPL activity and found
that there was an increase in the Adipoq-LPL mice, but it was
not significant (Fig. 6, p ⫽ 0.13).
Interestingly, neither PPAR␣- nor the PPAR␣-regulated
genes Aco, Cpt-1, and Ucp-1 were up-regulated in the AdipoqLPL mice (Table 4). PPAR␦ was induced, but Fiaf (Angplt4) and
Sirt1, which are regulated by PPAR␦, were not induced (Table
4). The expression of a number of mitochondrial genes was not
altered (Table 4). Finally, a number of inflammatory genes (IL1␤, MCP-1, and F4/80) was reduced in the Adipoq-LPL male
mice, but this did not reach significance (Table 4). Thus, the
epididymal fat pads of the male Adipoq-LPL mice had a pattern
of gene expression driven primarily by PPAR␥, resulting in
increased Adipoq and reduced inflammation. This pattern of
gene expression was not observed in subcutaneous adipose tissue of the male mice, although Adipoq mRNA expression was
higher in the SQ fat of the Adipoq-LPL mice (1.5-fold; p ⫽
0.113). This together with the increased adiponectin expression
in GO fat resulted in increased serum adiponectin in the male
Adipoq-LPL mice (Table 2).
The female Adipoq-LPL mice did not have increased PPAR␥
or PPAR␥-regulated gene (Adipoq and CD36) expression in
their abdominal fat. In fact, endogenous Lpl was decreased in
VOLUME 290 • NUMBER 18 • MAY 1, 2015
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FIGURE 3. Glucose and insulin tolerance of control and AdipoQ-LPL mice after HFD challenge. The mice were fed a HFD as described under “Experimental
Procedures.” A, glucose tolerance test of male mice after HFD (n ⫽ 6 control, six Adipoq-LPL; p ⫽ 0.0028 by repeated measures ANOVA). B, insulin tolerance test
on the same cohort of mice in A (p ⫽ 0.028 by repeated measures ANOVA). C, glucose tolerance test of female mice after HFD (n ⫽ 6 control, eight Adipoq-LPL;
p ⫽ 0.06 by repeated measures ANOVA). D, insulin tolerance on the same cohort of female mice in C. E, glucose tolerance test of male mice on chow diet (n ⫽
8 control, eight Adipoq-LPL; p ⫽ 0.99 by repeated measures ANOVA). F, insulin tolerance test on the same cohort of mice in E (p ⫽ 0.28 by repeated measures
ANOVA). The data are presented as means ⫾ S.E., and the results of a repeated measures ANOVA are indicated.

FIGURE 4. Ectopic lipids in control and AdipoQ-LPL mice after HFD challenge. Muscle (A) and liver (B) of control and Adipoq-LPL male mice from Fig.
2 were stained with Oil Red O as described under “Experimental Procedures.”
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female Adipoq-LPL mice (Table 5). However, there were trends
for decreased inflammatory gene expression, including IL-1␤
and MCP-1 (p ⫽ 0.08; Table 5), which were similar to the male
mice. Also, there was no difference in the fat or lean mass of the
control and Adipoq-LPL female mice at the end of the study
(Table 6). These results suggest a different mechanism for the
improved glucose tolerance observed in female Adipoq-LPL
mice.
Mechanism of Insulin Sensitization, Similar to TZD
Treatment?—The increase in PPAR␥-regulated genes observed
in the Adipoq-LPL mice is similar to pioglitazone treatment
(26). However, there was no increase in weight or adipose mass
(an undesirable side effect of TZD treatment) of the mice
(Table 2), which would be expected if LPL hydrolysis products
stimulated PPAR␥ as potently as TZDs. Because the free fatty
acids produced by LPL are likely weak PPAR␥ agonists (14), we
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TABLE 3
Tissue lipids

TABLE 4
Relative gene expression in perigonadal fat from male mice

Significant p values are in boldface type.
Lipida

a

Wild type

Significant p values are in boldface type.
Adipoq-LPL
transgenic

p

Muscle
TG
DAG
Ceramide

2.81 ⫾ 0.73
0.0036 ⫾ 0.0012
0.28 ⫾ 0.04

1.97 ⫾ 0.55
0.0028 ⫾ 0.0009
0.40 ⫾ 0.04

0.37
0.58
0.06

Liver
TG
DAG
Ceramide

0.10 ⫾ 0.02
0.00016 ⫾ 0.00003
0.0059 ⫾ 0.0005

0.34 ⫾ 0.09
0.00044 ⫾ 0.00014
0.0057 ⫾ 0.006

0.04
0.22
0.88

Tissues from male Adipoq-LPL transgenic mice and their littermate controls
were extracted for lipids and the extracts analyzed by mass spectrometry for
lipids from the liver and muscle as indicated after the 19-week high fat (60% kcal
fat) feeding study (n ⫽ 5 control and n ⫽ 6 Adipoq-LPL per group). The data are
means ⫾ S.E. The values are picomoles/nmol total phosphate.

Genea

Control

Adipoq-LPL

-Fold change
Tg/Control

PPAR␣
PPAR␦
PPAR␥1/2
PPAR␥-2
Aco
Cpt-1
Total Lplb
Mouse Lplc
CD36
Fabp4
Atgl
Adiponectin
Ucp3
Scd-1
Pepck
Angplt4
Sirt1
Ucp1
Pgc1␣
Glycerol kinase
Oxidized LDL receptor
F4/80
IL-1␤
Mcp-1
Atp5a1
Cyto c
Sdha
Vdac1

1.0 ⫾ 0.1
0.9 ⫾ 0.1
0.7 ⫾ 0.0
0.9 ⫾ 0.1
1.0 ⫾ 0.1
1.0 ⫾ 0.1
0.8 ⫾ 0.0
0.9 ⫾ 0.0
0.8 ⫾ 0.1
0.8 ⫾ 0.0
0.9 ⫾ 0.0
0.8 ⫾ 0.1
1.0 ⫾ 0.1
0.8 ⫾ 0.1
0.8 ⫾ 0.2
1.0 ⫾ 0.1
0.9 ⫾ 0.1
0.8 ⫾ 0.1
1.2 ⫾ 0.1
1.6 ⫾ 0.0
1.2 ⫾ 0.0
1.5 ⫾ 0.2
2.7 ⫾ 2.0
2.3 ⫾ 2.1
0.9 ⫾ 0.1
1.0 ⫾ 0.1
0.9 ⫾ 0.1
1.0 ⫾ 0.1

1.2 ⫾ 0.0
1.2 ⫾ 0.1
1.4 ⫾ 0.1
1.2 ⫾ 0.0
1.0 ⫾ 0.1
1.0 ⫾ 0.2
1.3 ⫾ 0.2
1.2 ⫾ 0.1
1.4 ⫾ 0.4
1.3 ⫾ 0.0
1.3 ⫾ 0.0
1.4 ⫾ 0.1
1.7 ⫾ 0.1
1.5 ⫾ 0.2
1.6 ⫾ 0.5
1.2 ⫾ 0.2
1.2 ⫾ 0.1
0.7 ⫾ 0.1
1.3 ⫾ 0.1
1.0 ⫾ 0.2
1.0 ⫾ 0.2
0.9 ⫾ 0.0
1.0 ⫾ 0.0
1.0 ⫾ 0.1
1.2 ⫾ 0.1
1.2 ⫾ 0.0
1.2 ⫾ 0.1
1.1 ⫾ 0.1

1.2
1.4
2.0
1.4
1.0
1.0
1.6
1.3
1.9
1.6
1.4
1.9
1.7
1.8
1.9
1.2
1.3
0.8
1.0
0.6
0.9
0.6
0.5
0.5
1.3
1.2
1.3
1.2

p
0.47
0.03
⬍0.01
⬍0.01
0.53
0.38
0.02
0.04
0.02
⬍0.01
0.08
⬍0.01
0.08
0.02
0.06
0.38
0.21
0.38
0.91
0.40
0.58
0.18
0.37
0.36
0.20
0.40
0.11
0.22

a

Epididymal fat pads from Adipoq-LPL transgenic mice and their littermate controls were characterized after 19 weeks of a high fat (60% kcal fat) feeding study
(n ⫽ 6 control; n ⫽ 6 Adipoq-LPL). The data are presented as means (arbitrary
units) ⫾ S.E.; the p value is for the difference in the mean.
b
Data were measured with a primer set that recognizes human (LPL transgene)
and mouse (endogenous) Lpl.
c
Data were measured with a primer set that recognizes mouse (endogenous) Lpl
3⬘UTR.

FIGURE 5. FPLC size exclusion chromatography analysis of sera from control and AdipoQ-LPL mice. The sera from the male mice in Fig. 2 were
resolved by size exclusion chromatography, and cholesterol (A) and triglycerides (B) were measured as described under “Experimental Procedures”; the
raw absorbance values are shown. Asterisk above the peaks indicates p ⬍
0.05).

determined whether the Adipoq-LPL mice had increased
expression of genes known to require the high potency of
TZDs, including glycerol kinase and the oxidized LDL receptor
(27–29). These were not up-regulated in the Adipoq-LPL transgenic mice (Table 4), suggesting that LPL selectively modulates
PPAR␥ to increase insulin sensitivity without side effects of full
PPAR agonism.
Metabolic Phenotype—A recent study suggests that altering
the tissue expression of LPL can affect energy balance (30).
Therefore, we next characterized the mice by indirect calorimetry after 12 weeks of HFD challenge; the mice were maintained
on the HFD while in the calorimetry chambers. The 24-h plots
are shown in Fig. 7. The data were then filtered by time
(between 9:00 a.m. and 6:00 p.m.) and activity (less than 150
counts for the previous 30 min) and then analyzed by
ANCOVA to determine whether resting energy expenditure
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FIGURE 6. Heparin-releasable LPL activity of epididymal fat of control
and AdipoQ-LPL mice. The heparin-releasable LPL activity in the epididymal
fat of male mice fed an HFD was measured as described under “Experimental
Procedures.” The data are presented as means ⫾ S.E.

was affected by genotype (Fig. 8A). The Adipoq-LPL mice had
increased resting energy expenditure (Fig. 8A, p ⫽ 0.044),
which was not due to increased activity (Fig. 8B). The increased
energy expenditure was also not due to either WAT browning
(Table 4) or brown fat activation in the Adipoq-LPL mice
because UCP1 and PGC1␣ were not induced there (Table 7).
Also, PPAR transcription factors and adiponectin were not significantly induced in BAT in the Adipoq-LPL mice, suggesting
that the LPL transgene effects are WAT-specific, consistent
with its expression in that depot. The Adipoq-LPL mice
weighed slightly more than the control mice (Fig. 8C, p ⫽
0.016); however, the Adipoq-LPL mice ate more during the
metabolic chamber study, which was significant when the data
were analyzed by ANCOVA using lean mass as a covariate (Fig.
VOLUME 290 • NUMBER 18 • MAY 1, 2015
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TABLE 5
Relative gene expression in perigonadal fat from female mice
Significant p values are in boldface type.

a

Genea

Control

AdipoQ-LpL

Fold change
TG/control

PPAR␣
PPAR␦
PPAR␥
CD36
Fabp4
Adiponectin
F4/80
IL-1␤
Mcp-1

1.5 ⫾ 0.4
1.5 ⫾ 0.3
.5 ⫾ 0.2
1.1 ⫾ 0.1
1.9 ⫾ 0.5
1.2 ⫾ 0.1
0.3 ⫾ 0.0
5.5 ⫾ 1.2
2.1 ⫾ 0.7

0.8 ⫾ 0.1
0.8 ⫾ 0.1
0.3 ⫾ 0.0
1.0 ⫾ 0.2
0.8 ⫾ 0.2
1.0 ⫾ 0.2
0.3 ⫾ 0.1
3.0 ⫾ 0.7
0.9 ⫾ 0.3

0.6
0.6
0.6
0.9
0.4
0.8
1.0
0.5
0.4

p
0.06
0.05
0.12
0.45
0.07
0.33
0.98
0.08
0.08

Perigonadal fat pads from female Adipoq-LPL transgenic mice and their littermate controls were characterized after 19 weeks of a high fat (60% kcal fat) feeding study (n ⫽ 6 control; n ⫽ 8 Adipoq-LPL). The data are presented as means
(arbitrary units) ⫾ S.E.; the p value is for the difference in the mean.

TABLE 6
Serum and mouse characterization of female mice

a

Parametera

Control

Adipoq-LPL

p

Serum
Fasting glucose (mg/dl)
Total triglycerides (mg/dl)
Total cholesterol (mg/dl)
Insulin (ng/ml)

197.4 ⫾ 5.8
204.3 ⫾ 30.0
153.0 ⫾ 19.2
0.53 ⫾ 0.09

195.8 ⫾ 9.9
161.8 ⫾ 21.4
128.9 ⫾ 12.0
0.73 ⫾ 0.17

0.88
0.26
0.33
0.37

Mouse characterization
Weight at end of study
Fat mass (ECHO MRI)
Lean mass (ECHO MRI)
% Fat (mean)

36.3 ⫾ 1.8
16.9 ⫾ 1.3
16.1 ⫾ 0.6
50.9 ⫾ 2.9

34.5 ⫾ 3.0
15.0 ⫾ 2.3
16.1 ⫾ 0.7
46.2 ⫾ 3.4

0.65
0.53
0.66
0.27

Adipoq-LPL female transgenic mice and their littermate controls were characterized in a 21-week high fat (60% cal fat) feeding study (n ⫽ 6 control and n ⫽ 8
Adipoq-LPL per group) that started at age 5 weeks. The data are presented as
means ⫾ S.E.; the p value is for the difference in the mean.

8D, p ⫽ 0.001). The resting respiratory exchange ratio was not
different between genotypes (p ⫽ 0.39).

DISCUSSION
Because LPL generates free fatty acids for TG synthesis in
adipocytes, an expected phenotype of the Adipoq-LPL mice
would be increased adipose mass and relief of lipotoxicity in a
high fat diet challenge. The Adipoq-LPL mice display no phenotype on chow and are protected against insulin and glucose
intolerance when challenged with a high fat diet. The mechanism of improvement does not involve reduction of ectopic
lipid accumulation in skeletal muscle or liver; plasma triglycerides and NEFAs were also not reduced in the Adipoq-LPL mice.
Furthermore, the Adipoq-LPL mice do not accumulate more fat
mass than the control mice; thus there is no evidence for lipid
diversion, which is most likely explained by the modest increase
in total LPL mRNA by the adiponectin promoter. Rather, the
Adipoq-LPL mice have beneficial adipose tissue phenotype that
is characterized by increased expression of adiponectin and
reduced adipose inflammation. The gene expression profile of
the epididymal fat suggests that the LPL transgene selectively
modulates PPAR␥ activity. This modified adipose phenotype
produces a systemic improvement in metabolism when the
mice are challenged with a high fat diet.
The results of this study suggest that increasing adipocyte
LPL in WAT results in improved glucose and insulin tolerance
in high fat diet-induced obesity. This is the opposite phenotype
of transgenic mice in which LPL was specifically induced in
muscle (muscle-LPL) or liver (liver-LPL), leading to insulin
MAY 1, 2015 • VOLUME 290 • NUMBER 18

resistance in those tissues (6). In the muscle-LPL and liver-LPL
models, the increased tissue lipid led to an increase in DAGs
and ceramides in the muscle and liver, respectively. Thus, one
mechanism that we evaluated was whether the Adipoq-LPL
mice had reduced ectopic lipids. However, we found no difference in Oil Red O staining; TG, DAG, and ceramide levels as
measured by mass spectroscopy; or plasma TG and NEFA.
Consistent with this, there was no increase in fat mass or
gonadal fat pad weight. The lack of lipid redistribution is likely
due to the fact that although the transgene is readily detectable
at both the message and protein level, it is only increasing the
overall message level modestly over endogenous Lpl (Table 4),
and we were not able to demonstrate a significant increase in
heparin releasable activity (Fig. 6). Thus, our transgene expression is not high enough to cause ectopic lipid redistribution.
Others have shown that increasing LPL globally in rabbits
improves glucose metabolism by reducing serum free fatty
acids (31).
Despite the fact that we did not see a lipid redistribution
effect, we did observe reduced cholesterol. A similar observation was made by Levak-Frank et al. (32), who found that
increasing muscle LPL expression increased HDL turnover. It
will be interesting to explore the mechanism in the future in the
Adipoq-LPL model because there have been different reports of
the effect of increasing LPL on HDL in other models, with some
models of LPL overexpression having no change in HDL (31, 33,
34) and one model reporting an increase in HDL (35).
To determine the mechanism for improved glucose metabolism, we evaluated whether the Adipoq-LPL transgene could
improve the WAT phenotype next. We extensively characterized gene expression in the WAT of the mice because LPL
hydrolysis products could stimulate PPAR transcription factors. Activation of these transcription factors in adipocytes
could promote insulin sensitivity by different mechanisms.
Stimulation of PPAR␥ could promote insulin sensitivity by
increasing adiponectin expression and/or other genes involved
in glucose homeostasis (36). PPAR␣ and PPAR␦ could promote
insulin sensitivity by stimulating the ␤-oxidation of fat (37, 38).
We observed that the Adipoq-LPL mice have increased gene
expression of a subset of PPAR-regulated genes. Absent from
this subset are genes that require the high affinity agonism of
TZDs such as glycerol kinase (28, 29). Glycerol kinase produces
glycerol 3-phosphate, which can then be used to re-esterify
fatty acids for storage as triglyceride, promoting weight gain.
Glycerol kinase is not up-regulated in the adipose of AdipoqLPL mice, whereas it is up-regulated in the adipose of TZDtreated mice (29). Also, Ucp1, which is induced by TZDs, was
not up-regulated in the Adipoq-LPL mice. However, Fabp4
(AP2) does not require high affinity ligands for its expression to
be induced (28), and Fabp4 was up-regulated in the AdipoqLPL transgenic male mice (Table 4). The results of our studies
suggest that the induction of LPL in adipose tissue increases a
select subset of endogenous PPAR␥ ligands to promote insulin
sensitivity without the side effects of high affinity TZD agonists.
This in part explains one of the remarkable features of the Adipoq-LPL mice; after high fat diet challenge, their fat mass is not
higher than the controls, which is a predicted side effect of
TZDs and an anticipated phenotype if increasing adipose LPL.
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FIGURE 7. 24-h energy metabolism data from control and Adipoq-LPL mice during HFD challenge. The mice were fed a high fat diet (60% calories from fat)
for 12 weeks prior to placing them in calorimetry chambers; the data were analyzed as described under “Experimental Procedures.” The mean data for the
control and Adipoq-LPL mice are plotted as a function of time.

FIGURE 8. Characterization of control and AdipoQ-LPL mice in calorimetry chambers during HFD challenge. A, data from Fig. 7 were filtered by time and
activity and analyzed with respect to the lean mass of the mice. Resting energy expenditure was plotted against post-lean mass; *, p ⫽ 0.044. B, average activity
of the mice. C, weight of the mice after the study; *, p ⫽ 0.016. D, net food intake during the study; *, p ⫽ 0.001.
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TABLE 7
Relative gene expression in BAT fat from male mice

a

Genea

Control

Adipoq-LPL

-Fold change
TG/Control

PPAR␣
PPAR␦
PPAR␥
Pgc1␣
Adiponectin
Ucp1
Ucp3

1.2 ⫾ 0.3
1.0 ⫾ 0.1
0.2 ⫾ 0.4
0.9 ⫾ 0.3
1.0 ⫾ 0.2
1.6 ⫾ 0.4
0.9 ⫾ 0.1

1.5 ⫾ 0.6
1.2 ⫾ 0.2
1.6 ⫾ 0.6
1.4 ⫾ 0.3
1.4 ⫾ 0.4
2.0 ⫾ 0.7
1.2 ⫾ 0.2

1.3
1.2
1.4
1.5
1.4
1.3
1.2

p
0.62
0.39
0.50
0.29
0.34
0.60
0.29

Epididymal fat pads from Adipoq-LPL transgenic mice and their littermate controls were characterized after 19 weeks of a high fat (60% kcal fat) feeding study
(n ⫽ 6 control; n ⫽ 6 Adipoq-LPL). The data are presented as means (arbitrary
units) ⫾ S.E.; the p value is for the difference in the mean.

After 12 weeks of HFD challenge, the AdipoQ-LPL mice had
higher energy expenditure than the controls. This response to
the increased LPL could be the result of adipose tissue trying to
defend its own mass (39) by increasing energy expenditure. The
increased energy expenditure does not involve increased activity. It also does not involve browning of the WAT depots
because Pgc1␣ and Ucp-1 were not increased there. Nor does it
involve BAT activation because Pgc1␣ and Ucp1 are not
increased in that depot. Also, unexpectedly, the LPL transgene
was not expressed in BAT, suggesting that diversion of lipid to
BAT is not occurring in the Adipoq-LPL mice. Of note, there
was no difference in weight loss while in the acclimation chambers or weight gain while in the metabolic chambers. One possibility for the increase in energy expenditure would be that the
improved WAT phenotype leads to this by an adipokine such as
adiponectin, which causes increased energy expenditure (40,
41). However, the anti-inflammatory phenotype could be
involved in this. This increase in energy expenditure is the
opposite phenotype to knocking down LPL in neurons (30), but
we did not find the transgene expressed in the brain, so the
mechanism remains to be determined. In addition to the
increase in energy expenditure, the Adipoq-LPL mice consumed more of the high fat diet. Thus, there is a futile cycle of
increased energy expenditure and increased food intake. Nevertheless, this mouse model could thus be a useful tool to
address the mechanism by which adipose defends its own mass
by increasing energy expenditure in response to increased LPL
in future studies.
In summary, increasing LPL in adipocytes improves adipose
function and protects against glucose and insulin intolerance in
diet-induced obesity. This occurs by the selective induction of
PPAR␥-regulated genes that lead to systemic improvements in
metabolism and increased energy expenditure. Identifying
these pathways and deciphering their contribution to regulation of metabolism is an important future goal. We are currently studying the acute response of this mouse model to high
fat diet using microarrays to better understand the mechanism
of the improved adipose phenotype.
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